New Inkjet-Printed Diagnostics-on-Demand Demonstrated at AACC 2015
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: The new “XylemDx” inkjet printing based technology turns a sheet of paper into any one of a variety of rapid, lower-cost tests. Each can be configured with a custom set of test modules before being folded concertina-style into the traditional test cartridge shape (Photo courtesy of Cambridge Consultants).

Image: Example of an open diagnostic test cartridge made using the breakthrough “XylemDx” inkjet printing based technology to custom-print any one of a variety of test modules onto a single sheet of paper (Photo courtesy of Cambridge Consultants).
An inkjet-based innovation for high-tech printing on paper opens the door to lower cost, rapid (point-of-care) POC testing, and was demonstrated during the 2015 AACC Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA).
The new XylemDx technology developed Cambridge Consultants (Cambridge, UK) is set to bring a breakthrough innovation to POC diagnostics. Ingenious use of inkjet printing techniques has made it possible to create a test cartridge from a single sheet of paper, paving the way for sophisticated low-cost tests that can be adapted at the touch of a button. Also, the digital fabrication technique (once regulatory approval is secured) will give the flexibility to print tests in quantities from one to millions.
Aging populations, the drive for healthcare efficiency, and the rapid rise of “consumer healthcare”—where people manage their own health and well-being—are fueling an increase in POC diagnostics. But the high cost of POC tests compared with centralized lab tests is a challenge. XylemDx enables simple, low-cost, near-instant personalized testing, for example, at the pharmacy or doctor’s surgery, for signs ranging from the latest strain of the flu virus to biomarkers for genetic conditions. In developing countries, it could play a crucial role in mobile-clinic diagnostics and in pandemic monitoring and screening of large populations during an outbreak of Ebola, for example.
XylemDx turns a sheet of paper into any one of a variety of different tests, each of which can be produced on the same fabrication device. Each test paper can be configured with a custom set of test modules (such as electronic, thermal, fluidic, optical, or biological reagent modules) before being folded concertina-style into the traditional test cartridge shape. For diagnostic manufacturers, this opens up the possibility of low-cost prototyping and development, as well as a universal production methodology. The modules “toolbox” enables customization for a particular patient or specific strain of disease.
The test modules are printed with inkjet-based printing techniques that use wax to lay down fluidic pathways, electronic ink containing silver nanoparticles to allow electrical connectivity, and so on. The paper cartridges can be configured for various samples types (such as blood, urine, saliva, or mucus) and various readers (from complex diagnostic instruments to a reader on the back of a smartphone or a simple USB-powered device).
“Diagnostic tests underpin crucial healthcare decisions so it’s vital they are as fast, accurate, flexible, and cost-effective as possible,” said John Pritchard, head of diagnostics at Cambridge Consultants, “Cambridge Consultants has a rich history of inkjet printing and we’ve now brought that expertise to the world of POC diagnostics. Combined with our extensive scientific and engineering knowledge—including our long track record in the low-cost, high-performance optics that many of these tests require—it’s resulted in a radical new way of providing diagnostics on demand.”
Related Links:
Cambridge Consultants
The new XylemDx technology developed Cambridge Consultants (Cambridge, UK) is set to bring a breakthrough innovation to POC diagnostics. Ingenious use of inkjet printing techniques has made it possible to create a test cartridge from a single sheet of paper, paving the way for sophisticated low-cost tests that can be adapted at the touch of a button. Also, the digital fabrication technique (once regulatory approval is secured) will give the flexibility to print tests in quantities from one to millions.
Aging populations, the drive for healthcare efficiency, and the rapid rise of “consumer healthcare”—where people manage their own health and well-being—are fueling an increase in POC diagnostics. But the high cost of POC tests compared with centralized lab tests is a challenge. XylemDx enables simple, low-cost, near-instant personalized testing, for example, at the pharmacy or doctor’s surgery, for signs ranging from the latest strain of the flu virus to biomarkers for genetic conditions. In developing countries, it could play a crucial role in mobile-clinic diagnostics and in pandemic monitoring and screening of large populations during an outbreak of Ebola, for example.
XylemDx turns a sheet of paper into any one of a variety of different tests, each of which can be produced on the same fabrication device. Each test paper can be configured with a custom set of test modules (such as electronic, thermal, fluidic, optical, or biological reagent modules) before being folded concertina-style into the traditional test cartridge shape. For diagnostic manufacturers, this opens up the possibility of low-cost prototyping and development, as well as a universal production methodology. The modules “toolbox” enables customization for a particular patient or specific strain of disease.
The test modules are printed with inkjet-based printing techniques that use wax to lay down fluidic pathways, electronic ink containing silver nanoparticles to allow electrical connectivity, and so on. The paper cartridges can be configured for various samples types (such as blood, urine, saliva, or mucus) and various readers (from complex diagnostic instruments to a reader on the back of a smartphone or a simple USB-powered device).
“Diagnostic tests underpin crucial healthcare decisions so it’s vital they are as fast, accurate, flexible, and cost-effective as possible,” said John Pritchard, head of diagnostics at Cambridge Consultants, “Cambridge Consultants has a rich history of inkjet printing and we’ve now brought that expertise to the world of POC diagnostics. Combined with our extensive scientific and engineering knowledge—including our long track record in the low-cost, high-performance optics that many of these tests require—it’s resulted in a radical new way of providing diagnostics on demand.”
Related Links:
Cambridge Consultants
Latest Technology News
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
Children are experiencing metabolic problems at increasingly younger ages, placing them at higher risk for serious health issues later in life. There is a growing need to identify this risk from birth... Read more
Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
Parkinson’s disease is a neurodegenerative condition typically diagnosed at an advanced stage based on clinical symptoms, primarily motor disorders. However, by this time, the brain has already undergone... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more